Form 4: Avidity Biosciences Director Simona Skerjanec Granted Stock Options

Director Simona Skerjanec received stock options for 42,308 shares of Avidity Biosciences (RNA) on May 14, 2024.

Summary

• On May 14, 2024, Simona Skerjanec, a director of Avidity Biosciences, Inc. (RNA), was granted stock options to purchase 42,308 shares of common stock.
• The exercise price of these options is $28.91 per share.
• The options vest in substantially equal monthly installments over three years from the grant date, contingent upon continuous service to the Issuer.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and generally viewed favorably as it aligns the interests of the director with those of the shareholders.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain talent, aligning the interests of employees and directors with those of the shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded biotechnology companies.
• The vesting schedule of three years is also typical in the industry, aligning with long-term value creation.
• Comparable companies such as Alnylam Pharmaceuticals and Ionis Pharmaceuticals also utilize stock options as part of their director compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the director to work towards increasing shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates